# Clinical pathology selected abstracts

written by CAP TODAY
July 18, 2025

July 2025—A large number of cancers remain undetected until later stages, including lung, colorectal, cervical, ovarian, pancreatic, and prostate cancers. The U.S. Preventive Services Task Force recommends screening based on age and other risk factors. It is estimated that more than 4 million cancers have been avoided due to early screening methods. Efforts are being made to develop cancer-screening tests that are easier to perform and less invasive and that detect multiple types of cancer, with the intent of reducing cancer-related morbidity and mortality. Multicancer early detection (MCED) assays depend on circulating cell-free DNA to detect a shared single cancer signal.




---

# Anatomic pathology selected abstracts

written by CAP TODAY
July 18, 2025

July 2025—Intraductal oncocytic papillary neoplasm of the pancreas is a recently recognized pancreatic tumor. The authors conducted a study to generate a comprehensive and quantitative summary of various aspects of intraductal oncocytic papillary neoplasms (IOPN). They searched the PubMed, Scopus, and Embase databases for studies reporting on pancreatic IOPN. Clinicopathologic, immunohistochemical, and molecular data were extracted from the studies and summarized. A comparative analysis of the molecular alterations of IOPN in juxtaposition with the typical molecular profile of conventional pancreatic ductal adenocarcinoma and intraductal papillary mucinous neoplasm from reference cohorts was subsequently conducted.

# Molecular pathology selected abstracts

written by CAP TODAY
July 18, 2025

July 2025—Liver damage can result in a build up of scar tissue, or fibrosis, a hallmark of chronic liver disease (CLD). The latter has been attributed to a variety of risk factors, including viruses (primarily hepatitis B and C), obesity, and alcohol abuse. Furthermore, some patients have a genetic predisposition for the disease. Alpha-1 antitrypsin (A1AT) deficiency and hereditary hemochromatosis are two such inherited disorders that cause hepatocyte stress and damage. In A1AT deficiency, mutations in the *SERPINA1* gene produce abnormal variants of the A1AT protein, which can accumulate in the liver and lead to hepatocyte damage. Mutations in the *HFE* gene are responsible for hereditary hemochromatosis.




# Pathology informatics selected abstracts

written by CAP TODAY
July 18, 2025

July 2025—Computational pathology has largely focused on analyzing tissue slides and overlooked worthwhile information in gross images. Recognizing this, the authors introduced a novel deep learning model based on Swin Transformer architecture and called Swin Transformer-based Gross Features Detective Network (SGFD-network). They sought to summarize and classify the gross examination characteristics of ovarian epithelial tumors by analyzing images of gross specimens using this deep learning approach. The SGFD-network is especially useful for distinguishing borderline tumors with microinvasive components from frank carcinomas. This capability is crucial during frozen section analysis, in which limited sampling and time pressures often challenge diagnostic accuracy.

---

# Q&A column

written by CAP TODAY
July 18, 2025

**July 2025**
**Q.** What is the best way to check machine precision? Is it acceptable to run precision replicates in quality control mode? Read answer.

**Q.** Several molecular diagnostic vendors circulate across U.S. hospitals and clinics to provide collection kits to physicians and request that those physicians refer tests outside the institution for what is sometimes described as clinical trials or research. The vendors operate using a pharmaceutical company model of selling proprietary testing directly to physicians and patients and bypassing the laboratory. It is a problem because laboratories are often expected to collect and submit samples and then enter complex reports into the electronic health record.

These companies are farming health systems for business and bypassing the accreditation process. When the testing is used not for research but instead for "the purpose of providing information for the diagnosis, prevention, or treatment of any disease or impairment of, or the assessment of the health of, human beings," under U.S. law it is defined as laboratory testing (section 353 of the Public Health Service Act, 42 USC §263a), which is overseen by pathology laboratories and under pathology's accreditation. Under this legal definition of laboratory testing, those outsourced tests are not research.

Can you comment on this practice from an accreditation perspective? Read answer.

CAP TODAY
Pathology • Laboratory Medicine • Laboratory Management



---

# Newsbytes

written by CAP TODAY
July 18, 2025

July 2025—PathAI and Chicago-based Northwestern Medicine have entered a multi-year venture in

which Northwestern will implement PathAI's AISight digital pathology image-management system. The two entities will also jointly undertake research initiatives and develop clinical innovation programs and artificial intelligence-powered diagnostic tools.




---

# Put It on the Board

written by CAP TODAY
July 18, 2025

July 2025—The length of time to install digital pathology equipment, interface, implement, train, and go live in 10 large laboratories ranged from under one year to about 18 months, and the time spent prior to that—evaluating options, gaining budget approval, making decisions, and completing the contract and negotiation process—took eight months to a year for seven of the 10. For two others, the evaluation, decision-making, and contracting process took about 18 months, and for one it took five years, largely owing to pandemic-related delay.




---

# Quest introduces testing for Oropouche virus

written by CAP TODAY
July 18, 2025

July 17, 2025—Quest Diagnostics has launched a diagnostic laboratory test for the Oropouche virus, an emerging virus in the Americas that is spread to people by infected biting midges and some species of mosquitoes.

# Register for our Upcoming Webinars

written by CAP TODAY
July 18, 2025

**Unlocking Fertility Insights:**
**The Power of AMH in Reproductive Health**

**Wednesday, September 24, 2025 1:00 PM–2:00 PM ET**

Webinar presenters **Wendy Vitek, MD,** Board-certified Reproductive Endocrinologist, Boston IVF's Syracuse, NY Fertility Center, and **Shirley Li, MD, PhD,** Associate Professor-Clinical, Department of Pathology; Director of Clinical Pathology Services and Co-Director of the Clinical Chemistry & Toxicology Laboratory, The Ohio State University, explore Anti-Müllerian Hormone (AMH) from both analytical and clinical perspectives. Gain insights into assay performance, method comparisons, and the practical utility of AMH in reproductive health and infertility treatment.

**Advances in AML Series**

**Tuesday, October 28, 2025 12:00 PM–1:00 PM ET**

Webinar presenter **Sanam Loghavi, MD,** Associate Professor, Dept. of Hematopathology Division of Pathology/Lab Medicine, MD Anderson Cancer Center, presents from a Pathologist's perspective, this program will allow you to learn and understand the following:

• Prevalence and severity of the FLT3-ITD mutation in AML
• Role of pathology in FLT3 mutation detection

• Patient identification and treatment landscape

# Waters, BD biosciences and diagnostic solutions to merge

written by CAP TODAY
July 18, 2025

July 15, 2025—Waters Corp. and BD announced a definitive agreement to combine BD's biosciences and diagnostic solutions business with Waters in a deal valued at approximately $17.5 billion.


©2026 CAP TODAY, all rights reserved.